Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases

 Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases

Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases

Shots:

  • Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more than ten programs
  • Bayer will get an exclusive option to license novel therapies derived from the research activities
  • The collaboration will deploy Recursion’s AI-guided drug discovery platform and Bayer’s small molecule compound library and expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Michigan Health Lab

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post